(HealthDay News) — Severe valvular heart disease (VHD) is prevalent among patients with cancer and is associated with reduced survival, according to a study presented at the annual congress of the ...

The BigpAK-2 randomized prospective multicenter trial tested implementation of a bundle of measures to prevent acute kidney injury in high-risk patients undergoing major surgery. Trial results support ...

(HealthDay News) — Zoliflodacin is noninferior to ceftriaxone plus azithromycin for the treatment of uncomplicated urogenital gonorrhea, according to a study published online Dec. 11 in The Lancet.

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

Biomarkers might improve risk stratification for patients with chronic kidney disease (CKD) at cardiovascular risk.

FDA expands Accrufer approval to treat iron deficiency in pediatric patients aged 10 years and older based on phase 3 FORTIS trial outcomes.

The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.

(HealthDay News) — Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated fat intake can reduce mortality and major cardiovascular ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users.

Diagnostic evaluation should follow principle of 'as low as reasonably achievable'; systemic therapy should be deferred until second trimester.

Minimally invasive surgery linked to lower major complication risk, reduced length of stay, decreased transfusion rate.

Nivolumab plus cabozantinib showed the largest OS advantage, whereas lenvatinib plus pembrolizumab yielded the greatest PFS benefit. First-line immune checkpoint inhibitor (ICI) combinations for ...